Results 171 to 180 of about 56,817 (261)

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

When GUI‐Based Testing of Web Applications Meets Code Review

Software Testing, Verification and Reliability, Volume 36, Issue 5, August 2026.
Summary of our findings on practices, challenges, information needs and future improvements for code review of GUI‐based testing artefacts. ABSTRACT Code review is a well‐established practice to ensure code quality, identify potential bugs, promote knowledge sharing and maintain coding standards within a team or organization.
Andreas Bauer, Tomas Helmfridsson, Emil Alégroth, Georg‐Daniel Schwarz   +3 more
wiley   +1 more source

Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy. [PDF]

Hepatol Commun
Shigeno S, Kodama T, Murai K, Sometani E, Yasuda K, Tahata Y, Nishio A, Tanaka S, Miyazaki M, Ohkawa K, Kakita N, Tawara S, Yakushijin T, Hikita H, Toyoda H, Takehara T.   +15 more
europepmc   +1 more source

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off‐label pegylated interferon alpha was the primary treatment option in Europe prior to the introduction of bulevirtide, a first‐in‐class HDV entry inhibitor.
Monica Radu, Margarita Papatheodoridi, Habiba Kamal Khodir, Sabela Lens, Elisabetta Degasperi, Speranta Iacob, Liliana Gheorghe, Katja Steppich, Florin Alexandru Caruntu, Pietro Lampertico, Soo Aleman, Heiner Wedemeyer   +11 more
wiley   +1 more source

Novel Spiral and Embracing IDE Capacitive Sensors for In Situ Measurement of Soil Moisture. [PDF]

Sensors (Basel)
Xu Y, He Y, Li X, Tu Y, Zhang K, Liu Y, Sun Y.   +6 more
europepmc   +1 more source

Evolution of Coupled Seismic‐Aseismic Slip During the 2025 Mw 6.8 Sanriku‐Oki, Japan, Megathrust Sequence

Geophysical Research Letters, Volume 53, Issue 13, 16 July 2026.
Abstract On 9 November 2025, a Mw 6.8 Sanriku‐Oki earthquake struck a Japan Trench segment with inferred recurrent aseismic slip and Mw ∼7 earthquakes. Using S‐net seafloor data, we examine the preparatory and post‐mainshock evolution of this foreshock–mainshock–aftershock sequence.
Keisuke Yoshida
wiley   +1 more source

Outcomes of Nucleos(t)ide Analogue Discontinuation in Noncirrhotic Patients With Chronic Hepatitis B: A Retrospective Study. [PDF]

Cureus
Bhatt S, Sonika U, Vaithiyam V, Srivastava S, Patel D, Dalal A, Kumar A, Sharma BC, Sachdeva S.   +8 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Efficacy and Safety of Paclitaxel-Coated Balloon Angioplasty in Patients With In-Stent Restenosis With vs Without Diabetes. [PDF]

J Soc Cardiovasc Angiogr Interv
Gaba P, Jefferson BK, Shlofmitz R, Moses JW, Bachinsky W, Dohad S, Rudick S, Stoler R, Nicholson W, Altman J, Bateman C, Krishnaswamy A, Cavalcante R, Yeh RW, Kirtane AJ.   +14 more
europepmc   +1 more source